我国近期医药产业政策对制药企业创新影响的实证研究  

An empirical study on the impacts of recent pharmaceutical industry policies on the pharmaceutical companies in China

作　　者：陈昌雄[1] 史录文[1] 

机构地区：[1]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国新药杂志》2013年第12期1376-1382,共7页Chinese Journal of New Drugs

摘　　要：本文首先界定了医药产业政策,梳理了我国近期影响医药创新主要的医药政策。在此基础上,重点通过对部分制药企业进行问卷调查,运用SAS系统作为分析工具,采用多元线性回归分析方法,探求国家政策支持与企业创新能力之间的关系。研究表明,国家的政策支持确实促进制药企业的创新发展。At first, we defined the pharmaceutical industry policy and trimmed the recent main policies concerned with pharmaceutical innovation in China. Then, in order to research the exact effects of the policies on the pharmaceutical companies, we did questionnaire with some enterprises. By means of the analysis tool SAS and the analysis method of multiple linear regression, we tried to find out the relationship between the national policy support and the innovation ability of the pharmaceutical companies. The result is that the government＇s policy sup- port indeed has promoted the creative development of the pharmaceutical companies.

关 键 词：医药产业政策 医药创新 制药企业 影响 

分 类 号：R95[医药卫生—药学]